Rystiggo (rozanolixizumab-bg) is a medication used to treat adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or anti-muscle-specific kinase (MuSK) positive.
What is Rystiggo used for?
Rystiggo is indicated for the treatment of adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or anti-muscle-specific kinase (MuSK) positive [1]. Generalized myasthenia gravis is a chronic autoimmune disease that causes weakness in the skeletal muscles responsible for breathing and controlling body movements [2].
Who manufactures Rystiggo?
Rystiggo is manufactured by UCB Pharma [1].
Are there manufacturer coupons or savings programs for Rystiggo?
Information on specific manufacturer coupons or savings programs for Rystiggo is not publicly detailed. However, UCB Pharma offers patient support programs that may provide financial assistance to eligible individuals. These programs can help reduce out-of-pocket costs for patients prescribed UCB medications. To inquire about current savings programs and eligibility criteria, patients and healthcare providers can contact UCB's patient support services directly. Details about UCB's patient support can often be found on the manufacturer's official website or through your prescribing physician's office [3].
How does Rystiggo work?
Rystiggo is a monoclonal antibody that binds to the neonatal Fc receptor (FcRn) [1]. By inhibiting the binding of FcRn to immunoglobulin G (IgG), Rystiggo facilitates the degradation of IgG, thereby reducing pathogenic autoantibodies that are a hallmark of gMG [1][2].
What are the clinical trial results for Rystiggo?
Clinical trials demonstrated Rystiggo's efficacy in improving gMG symptoms. In the Phase 3 MYRA study, Rystiggo met its primary endpoint, showing a statistically significant improvement in the uppercase Myasthenia Gravis-Activities of Daily Living (MG-ADL) score compared to placebo after six weeks of treatment in patients with anti-AChR antibodies [4]. The Phase 3 MARINA study also showed significant improvements in MG-ADL scores for MuSK-positive gMG patients [4].
What are the potential side effects of Rystiggo?
Common side effects associated with Rystiggo treatment include infections (such as upper respiratory tract infections, urinary tract infections, and nasopharyngitis), headache, diarrhea, and rash [1]. Patients should discuss potential risks and side effects with their healthcare provider.
How is Rystiggo administered?
Rystiggo is administered as a subcutaneous infusion [1].
When was Rystiggo approved?
Rystiggo received U.S. Food and Drug Administration (FDA) approval in June 2023 [5].
What is the patent status of Rystiggo?
Information regarding specific patents for Rystiggo and their expiry dates can be found through specialized drug patent tracking resources. Such databases can provide details on patent filings, granted patents, and expected patent expiry, which is crucial for understanding market exclusivity and the potential for generic competition. Resources like DrugPatentWatch.com track these details [6].
---
Sources:
[1] https://www.rystiggo.com/
[2] https://www.ninds.nih.gov/health-information/disorders/myasthenia-gravis
[3] UCB Pharma Patient Support Information (Specific link may vary, typically found on UCB's official website or through physician referral)
[4] https://www.ucb.com/stories-news/press-releases/UCB-announces-RYSTIGGO-rozanolixizumab-bg-receives-US-FDA-approval-for-adults-with-generalized-myasthenia-gravis
[5] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals-and-certifications
[6] https://www.drugpatentwatch.com/